An Open-Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate Gel 0.05% for the Treatment of Verruca Vulgaris

Neal D. Bhatia, MD
Director, Clinical Dermatology; Therapeutics Clinical Research, San Diego, CA

INTRODUCTION

Verruca vulgaris is caused by the human papillomavirus (HPV) and is most frequently associated with HPV types 1, 2, 4, 27, 29, and 57.1 It commonly occurs on the hands.1,2 Current therapies are aimed at destroying tissue or inducing the body’s inflammatory response against the virus. There is no FDA-approved topical therapy for common warts.2 Ingenol mebutate gel 0.05% is FDA approved for the topical treatment of actinic keratosis (AK)3 and has a dual mechanism of action: (1) induction of rapid lesion necrosis followed by (2) an inflammatory reaction thought to be mediated by protein kinase C activation.4 HPV-infected keratinocytes behave similarly to keratinocytes damaged by UV in the pathogenesis of AK. These similarities include hyperproliferation and mutagenesis5;6,11 therefore, cytotoxicity of target tissue using an AK topical treatment might be beneficial in wart destruction.

A recent case study showed the efficacy of ingenol mebutate against anogenital warts.1,2 The current study was an open-label, exploratory study using ingenol mebutate gel 0.05% for the treatment of verruca vulgaris on the hands.

METHODS

Design

Open-label, exploratory study (Figure 1) Conducted at a single site in the US in 2016-2017 16 eligible subjects were treated once daily for 2 consecutive days, on days 1 and 2 of the study, with ingenol mebutate gel 0.05% Warts were pared to allow for effective penetration without the callus – Additionally, one wart in each subject was occluded with a standard adhesive bandage for 24 hours after each application Follow-up visits occurred on days 8, 29, and 57 to assess application-site reactions (ASRs)

At day 57 (study end), wart clearance was assessed

Figure 1. Study design

Safety

• Visual assessment of ASRs on a 5-point scale (% clear to 4+ severe) (days 1, 2, 29, 57)
• Adverse events were recorded

Questionnaire

• 6-question survey on patient satisfaction (at study end, day 57)

Primary efficacy end point

• Complete clearance of all warts

RESULTS

Table 1. Baseline subject demographics and characteristics

<table>
<thead>
<tr>
<th>Category</th>
<th>n</th>
<th>(% or mean)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>41.17</td>
<td>(37.5)</td>
</tr>
<tr>
<td>Gender, female, n (%)</td>
<td>41.17</td>
<td>(37.5)</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td>14 (87.5)</td>
<td>1 (6.3)</td>
</tr>
<tr>
<td>Native, n (%)</td>
<td>13 (81.25)</td>
<td>1 (6.3)</td>
</tr>
<tr>
<td>Number of warts at baseline</td>
<td>Mean</td>
<td>5.38</td>
</tr>
<tr>
<td>Size of warts, mm² (mean)</td>
<td>0.3</td>
<td></td>
</tr>
</tbody>
</table>

Treatment regimen

Subjects were treated from April 2016 to January 2017 Treatment began after subjects met key inclusion criteria of confirmed common warts Of the identified 54 warts, 16 lesions were occluded and 38 lesions were not occluded – Ingenol mebutate gel 0.05% was applied to the lesion, plus a 0.5-cm margin – Duration of treatment: once daily for 2 consecutive days, on days 1 and 2 of the study – A maximum of one treatment kit (containing 2 tubes of medication) was used

Primary efficacy end point

The primary end point of complete clearance of all warts was not met in any of the 16 subjects However, overall wart count was reduced from 54 at baseline to 40 at study end, a 26% reduction in wart count (Figure 2A)

Warts reduced in size

Of the non-occluded warts, 57% (30/52) showed a partial reduction in size; they were reduced by 42% in size (Figure 2B) Of the occluded warts, 50% (8/16) showed a partial reduction in size; they were reduced by 45% in size (Figure 2B)

Figure 2. Ingenol mebutate gel 0.05% efficacy for treatment of warts

Subject satisfaction

11 of the 16 subjects stated that the wart treatment was tolerable or very tolerable 8 of the 16 subjects noted that the use of the bandage was moderately to extremely difficult during the 2 days of treatment

Satisfaction with treatment results

– Neutral 7 of 16 subjects
– Moderately or very satisfied 5 of 16 subjects
– Disappointed 4 of 16 subjects

7 of 16 subjects preferred this treatment over previous topical treatments or office procedures, with 5 strongly preferring and 2 slightly or moderately preferring this treatment

ASRs

ASRs were defined as erythema, flaking/scaling, crusting, swelling, erosion/ ulceration and vesiculation/pustulation All subjects experienced ASRs that began on day 2 of treatment ASRs peaked within 6 days (Figure 3) and resolved without relief treatment, with the exception of 2 subjects who required lysis of bullae ASRs most commonly reported were severe swelling (3/16) and vesiculation/ pustulation (3/16) on day 3 Follow-up

All ASRs were clinically resolved at short-term follow-up at 3 to 4 weeks No adverse effects were reported

DISCUSSION

The mechanism of action of ingenol mebutate in AK is often referred to as dual action: rapid lesion necrosis and then activation of the innate immune system via a specific neutrophil-mediated antibody-dependent cellular cytotoxicity.7 Protein kinases play a fundamental role in the mechanism of action of ingenol mebutate treatment and the cell death of primary keratinocytes and patient-derived squamous cell carcinoma cell lines.8,9 HPV-infected keratinocytes behave similarly to UV-damaged keratinocytes in AK. Given their similarities in mutagenesis and hyperproliferation,1 7–10 the cytotoxicity of target tissue with ingenol mebutate was hypothesized to be beneficial in wart destruction

The primary end point of complete clearance of all warts was not met in any of the 15 subjects in this study. However, overall wart count was reduced from 54 at baseline to 40

Of the occluded warts, 81.25% (13/16) were reduced in size from baseline, with 50% (8/16) showing a partial reduction in size; they were reduced by 42% in size (Figure 2B) Of the non-occluded warts, 57% (30/52) showed a partial reduction in size; they were reduced by 42% in size (Figure 2B)

CONCLUSION

• Ingenol mebutate gel 0.05% was efficacious and well tolerated for the overall size of warts

• The occlusion treatment was associated with increased efficacy and anticipated ASRs

• The majority of subjects found the treatment to be tolerable or very tolerable

References


Acknowledgments

We acknowledge the help of Bethany Parker, Nicole Yagodiak, and Dr. Nadia Zorovina on this project. Writing support was provided by Juhl Communications and funded by Leo Pharma Inc.

Poster was originally presented at Maui Derm for Dermatologists; March 20-24, 2017; Maui, Hawaii.